{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:44:04Z","timestamp":1790462644339,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Oncology Nursing"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.ejon.2006.10.004","type":"journal-article","created":{"date-parts":[[2007,3,10]],"date-time":"2007-03-10T06:55:51Z","timestamp":1173509751000},"page":"238-246","source":"Crossref","is-referenced-by-count":107,"title":["Palmar\u2013plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre"],"prefix":"10.1016","volume":"11","author":[{"given":"Joan D.","family":"Webster-Gandy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"How","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Harrold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejon.2006.10.004_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1081\/CNV-120000360","article-title":"Incidence and severity of hand\u2013foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience","volume":"20","author":"Abushullaih","year":"2002","journal-title":"Cancer Investigation"},{"key":"10.1016\/j.ejon.2006.10.004_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1191\/096032799678839347","article-title":"Relationship of dose intensity to the induction of palmar\u2013plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs","volume":"18","author":"Amantea","year":"1999","journal-title":"Human and Experimental Toxicology"},{"key":"10.1016\/j.ejon.2006.10.004_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.1991.9.4.625","article-title":"A phase-ii study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal-carcinoma","volume":"9","author":"Ardalan","year":"1991","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1468-3083.1997.tb00494.x","article-title":"Acral erythema and intrahepatic 5-fluorouracil infusion","volume":"8","author":"Arias","year":"1997","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1016\/j.ejon.2006.10.004_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1600-0560.1999.tb01846.x","article-title":"Expression and localization of thymidine phosphorylase\/platelet-derived endothelial cell growth factor in skin and cutaneous tumors","volume":"26","author":"Asgari","year":"1999","journal-title":"Journal of Cutaneous Pathology"},{"key":"10.1016\/j.ejon.2006.10.004_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/0003-4819-102-3-419_1","article-title":"Fluorouracil and the palmar\u2013plantar erythrodysesthesia syndrome","volume":"102","author":"Atkins","year":"1985","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.ejon.2006.10.004_bib7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1046\/j.1365-2230.1999.00419.x","article-title":"Chemotherapy-induced acral erythema (CIAE) with bullous reaction","volume":"24","author":"Azurdia","year":"1999","journal-title":"Clinical and Experimental Dermatology"},{"key":"10.1016\/j.ejon.2006.10.004_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0190-9622(91)70073-B","article-title":"Chemotherapy-induced acral erythema","volume":"24","author":"Baack","year":"1991","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.ejon.2006.10.004_bib9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.7326\/0003-4819-102-4-556_1","article-title":"Palmar\u2013plantar erythrodysesthesia and cytarabine","volume":"102","author":"Baer","year":"1985","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.ejon.2006.10.004_bib10","first-page":"356","article-title":"Long-term sequelae of palmar\u2013plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy","volume":"88","author":"Banfield","year":"1995","journal-title":"Journal of the Royal Society of Medicine"},{"key":"10.1016\/j.ejon.2006.10.004_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2340\/00015555777273","article-title":"Chemotherapy-induced acral erythema due to Tegafur","volume":"77","author":"Bastida","year":"1997","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1016\/j.ejon.2006.10.004_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/030089168807400315","article-title":"Palmar\u2013plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil","volume":"74","author":"Bellmunt","year":"1988","journal-title":"Tumori"},{"key":"10.1016\/j.ejon.2006.10.004_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0190-9622(08)80126-0","article-title":"Treatment of cytarabine acral erythema with corticosteroids","volume":"24","author":"Brown","year":"1991","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.ejon.2006.10.004_bib15","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin","volume":"13","author":"Cassidy","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib16","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1124\/jpet.103.053413","article-title":"Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity","volume":"306","author":"Charrois","year":"2003","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.ejon.2006.10.004_bib17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0959-8049(96)00497-2","article-title":"Hand\u2013foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion","volume":"33","author":"Chiara","year":"1997","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.ejon.2006.10.004_bib88","first-page":"409a","article-title":"Use of \u2018Bag Balm\u2019 as topical treatment of palmar-plantar erythrodysesthesia syndrome (PPES) in patients receiving selected chemotherapeutic agents","volume":"20","author":"Chin","year":"2001","journal-title":"Proceedings of the American Society for Clinical Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib18","first-page":"1781","article-title":"Palmar\u2013plantar erythrodysestasia syndrome-associated with 5-fluorouracil treatment","volume":"13","author":"Comandone","year":"1993","journal-title":"Anticancer Research"},{"key":"10.1016\/j.ejon.2006.10.004_bib19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2165\/00003495-199753030-00011","article-title":"Polyethylene glycol-liposomal doxorubicin\u2014a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma","volume":"53","author":"Coukell","year":"1997","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ejon.2006.10.004_bib20","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archderm.122.12.1413","article-title":"Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy","volume":"122","author":"Cox","year":"1986","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.ejon.2006.10.004_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1034\/j.1600-0609.2002.02834.x","article-title":"Recurrent palmar\u2013plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia","volume":"69","author":"Crawford","year":"2002","journal-title":"European Journal of Haematology"},{"key":"10.1016\/j.ejon.2006.10.004_bib22","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-111-10-858_1","article-title":"Fluorouracil and palmar\u2013plantar erythrodysesthesia","volume":"111","author":"Curran","year":"1989","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.ejon.2006.10.004_bib23","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/sj.bjc.6601284","article-title":"Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer","volume":"89","author":"D\u2019Agostino","year":"2003","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.ejon.2006.10.004_bib24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00216925","article-title":"Pyridoxine therapy for palmar\u2013plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion","volume":"8","author":"Fabian","year":"1990","journal-title":"Investigational New Drugs"},{"key":"10.1016\/j.ejon.2006.10.004_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00002820-200304000-00011","article-title":"Current Canadian experience with capecitabine: partnering with patients to optimize therapy","volume":"26","author":"Gerbrecht","year":"2003","journal-title":"Cancer Nursing"},{"key":"10.1016\/j.ejon.2006.10.004_bib26","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.ejon.2004.06.010","article-title":"Implications of capecitabine (XELODA) for cancer nursing practice","volume":"8","author":"Gerbrecht","year":"2004","journal-title":"European Journal of Oncology Nursing"},{"key":"10.1016\/j.ejon.2006.10.004_bib27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1592\/phco.21.7.751.34572","article-title":"Pegylated liposomal doxorubicin: tolerability and toxicity","volume":"21","author":"Goram","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejon.2006.10.004_bib28","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO;2-H","article-title":"Hand\u2013foot syndrome-associated with liposome-encapsulated doxorubicin therapy","volume":"75","author":"Gordon","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ejon.2006.10.004_bib29","first-page":"216","article-title":"Continuous 5-fluorouracil infusion and pulse methotrexate leucovorin for colorectal adenocarcinoma\u2014a report of excessive toxicity","volume":"10","author":"Hansen","year":"1987","journal-title":"American Journal of Clinical Oncology\u2014Cancer Clinical Trials"},{"key":"10.1016\/j.ejon.2006.10.004_bib30","first-page":"19","article-title":"Development of a nurse-led service for patients receiving oral capecitabine","volume":"1","author":"Harrold","year":"2002","journal-title":"Cancer Nursing Perspective"},{"key":"10.1016\/j.ejon.2006.10.004_bib31","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/archderm.132.5.590","article-title":"High-dose methotrexate-induced bullous variant of acral erythema","volume":"132","author":"Hellier","year":"1996","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.ejon.2006.10.004_bib32","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<965::AID-CNCR23>3.0.CO;2-Y","article-title":"Hand\u2013foot syndrome following prolonged infusion of high doses of vinorelbine","volume":"82","author":"Hoff","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ejon.2006.10.004_bib33","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib34","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1592\/phco.20.15.1221.34593","article-title":"Palmar\u2013plantar erythrodysesthesia syndrome associated with liposomal daunorubicin","volume":"20","author":"Hui","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejon.2006.10.004_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1014421912799","article-title":"Chemotherapy-induced palmar\u2013plantar erythrodysesthesia syndrome: recall following different chemotherapy agents","volume":"20","author":"Hui","year":"2002","journal-title":"Investigational New Drugs"},{"key":"10.1016\/j.ejon.2006.10.004_bib36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1345\/aph.18281","article-title":"Acral erythema associated with high-dose methotrexate infusion","volume":"33","author":"Ikeda","year":"1999","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1016\/j.ejon.2006.10.004_bib37","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3109\/02841869709001331","article-title":"Palmar\u2013plantar erythrodysaesthesia syndrome due to 5-fluorouracil therapy\u2014an underestimated toxic event?","volume":"36","author":"Iurlo","year":"1997","journal-title":"Acta Oncologica"},{"key":"10.1016\/j.ejon.2006.10.004_bib38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/archderm.131.3.364","article-title":"Palmoplantar keratoderma secondary to chronic acral erythema due to Tegafur","volume":"131","author":"Jucgla","year":"1995","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.ejon.2006.10.004_bib39","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1346-8138.2004.tb00692.x","article-title":"A case of docetaxel-induced erythrodysesthesia","volume":"31","author":"Katohm","year":"2004","journal-title":"Journal of Dermatology"},{"key":"10.1016\/j.ejon.2006.10.004_bib40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1067\/mjd.2003.30","article-title":"Scleroderma-like cutaneous lesions induced by paclitaxel: a case study","volume":"48","author":"Kupfer","year":"2003","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.ejon.2006.10.004_bib41","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1023\/A:1013575816870","article-title":"Hand\u2013foot syndrome associated with short infusions of combination chemotherapy with gemcitabine and vinorelbine","volume":"12","author":"Laack","year":"2001","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib42","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ejon.2004.06.007","article-title":"Management of hand\u2013foot syndrome in patients treated with capecitabine (XELODA)","volume":"8","author":"Lassere","year":"2004","journal-title":"European Journal of Oncology Nursing"},{"key":"10.1016\/j.ejon.2006.10.004_bib43","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/1120009X.1994.11741178","article-title":"Dermatological toxicity from chemotherapy containing 5-fluorouracil","volume":"6","author":"Leo","year":"1994","journal-title":"Journal of Chemotherapy"},{"key":"10.1016\/j.ejon.2006.10.004_bib44","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1200\/JCO.1989.7.4.425","article-title":"A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal-carcinoma\u2014a mid-atlantic oncology program study","volume":"7","author":"Lokich","year":"1989","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib45","doi-asserted-by":"crossref","first-page":"798","DOI":"10.7326\/0003-4819-101-6-798","article-title":"Chemotherapy-associated palmar\u2013plantar erythrodysesthesia syndrome","volume":"101","author":"Lokich","year":"1984","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.ejon.2006.10.004_bib46","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s002800050981","article-title":"Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar\u2013plantar erythrodysesthesia","volume":"44","author":"Lopez","year":"1999","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.ejon.2006.10.004_bib47","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3816\/CBC.2003.n.019","article-title":"A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer","volume":"4","author":"Lorusso","year":"2003","journal-title":"Clinical Breast Cancer"},{"key":"10.1016\/j.ejon.2006.10.004_bib48","first-page":"33","article-title":"Toxicity of 5-fluorouracil","volume":"13","author":"Macdonald","year":"1999","journal-title":"Oncology\u2014New York"},{"key":"10.1016\/j.ejon.2006.10.004_bib49","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00280-004-0858-2","article-title":"Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible?","volume":"55","author":"Marigny","year":"2005","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.ejon.2006.10.004_bib50","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.ejon.2004.06.006","article-title":"Management of adverse events and other practical considerations in patients receiving capecitabine (XELODA)","volume":"8","author":"Marse","year":"2004","journal-title":"European Journal of Oncology Nursing"},{"key":"10.1016\/j.ejon.2006.10.004_bib51","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdh092","article-title":"Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer","volume":"15","author":"Matsumura","year":"2004","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib52","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000059568","article-title":"Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (Caelyx) administered every 2 weeks in patients with advanced solid tumors","volume":"62","author":"Mavroudis","year":"2002","journal-title":"Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib53","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","article-title":"Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors","volume":"16","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib54","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ygyno.2004.02.019","article-title":"The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma","volume":"93","author":"Molpus","year":"2004","journal-title":"Gynecologic Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib55","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2141.1991.tb08621.x","article-title":"The toxicity of busulfan and cyclophosphamide as the preparative regimen for bone-marrow transplantation","volume":"77","author":"Morgan","year":"1991","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.ejon.2006.10.004_bib56","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00043426-200203000-00018","article-title":"Bullous acral erythema secondary to high-dose methotrexate","volume":"24","author":"Morrell","year":"2002","journal-title":"Journal of Pediatric Hematology Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF02994097","article-title":"Weekly fluorouracil and high-dose leucovorin\u2014efficacy and treatment of cutaneous toxicity","volume":"26","author":"Mortimer","year":"1990","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.ejon.2006.10.004_bib58","first-page":"753","article-title":"Capecitabine: nursing implications of a new oral chemotherapeutic agent","volume":"26","author":"Mrozek-Orlowski","year":"1999","journal-title":"Oncology Nursing Forum"},{"key":"10.1016\/j.ejon.2006.10.004_bib59","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1002\/1097-0142(19930515)71:10<3153::AID-CNCR2820711042>3.0.CO;2-#","article-title":"Dose-related cutaneous toxicities with etoposide","volume":"71","author":"Murphy","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ejon.2006.10.004_bib60","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","article-title":"Antineoplastic therapy-induced palmar\u2013plantar erythrodysesthesia (\u2018hand\u2013foot\u2019) syndrome. Incidence, recognition and management","volume":"1","author":"Nagore","year":"2000","journal-title":"American Journal of Clinical Dermatology"},{"key":"10.1016\/j.ejon.2006.10.004_bib61","unstructured":"National Cancer Institute, 1999. Common Toxicity Criteria. Cancer Therapy Evaluation Programme."},{"key":"10.1016\/j.ejon.2006.10.004_bib62","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1023\/A:1012281104865","article-title":"Randomized, open-label, phase II trial of oral capecitabine (Xeloda(R)) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced\/metastatic breast cancer","volume":"12","author":"O\u2019Shaughnessy","year":"2001","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib63","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O\u2019Shaughnessy","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib64","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdg446","article-title":"High incidence of severe hand\u2013foot syndrome during capecitabine\u2013docetaxel combination chemotherapy","volume":"14","author":"Park","year":"2003","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1016\/j.ejon.2006.10.004_bib89","first-page":"1519","article-title":"Clinical challenges. Hand-foot syndrome\u2026 palmar-plantar erythrodysesthesia","volume":"28","author":"Pike","year":"2001","journal-title":"Oncology Nursing Forum"},{"key":"10.1016\/j.ejon.2006.10.004_bib65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00685939","article-title":"Etoposide-related acral erythema","volume":"34","author":"Portal","year":"1994","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.ejon.2006.10.004_bib66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/08880010590907320","article-title":"Acral erythema caused by high-dose methotrexate therapy in patients with osteogenic sarcoma","volume":"22","author":"Postovsky","year":"2005","journal-title":"Pediatric Hematology and Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib67","first-page":"770","article-title":"Phase-1 study of continuous-infusion 6-thioguanine in patients with acute-leukemia","volume":"9","author":"Powell","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.ejon.2006.10.004_bib68","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2340\/00015555778081","article-title":"Palmar\u2013plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur","volume":"77","author":"RiosBuceta","year":"1997","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1016\/j.ejon.2006.10.004_bib90","unstructured":"Roche Laboratories, 2006. Xeloda(r) product information. Retrieved from http:\/\/www.rocheusa.com\/products\/xeloda\/pi.pdf."},{"key":"10.1016\/j.ejon.2006.10.004_bib69","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<1054::AID-CNCR40>3.0.CO;2-3","article-title":"Hand\u2013foot syndrome following prolonged infusion of high doses of vinorelbine","volume":"83","author":"Rosner","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ejon.2006.10.004_bib70","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdg500","article-title":"Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial","volume":"14","author":"Scheithauer","year":"2003","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib71","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1600-0609.1992.tb00578.x","article-title":"The handfoot syndrome occurring with chronic administration of etoposide","volume":"48","author":"Schey","year":"1992","journal-title":"European Journal of Haematology"},{"key":"10.1016\/j.ejon.2006.10.004_bib72","doi-asserted-by":"crossref","first-page":"675","DOI":"10.7326\/0003-4819-98-5-675_2","article-title":"Acral erythema and hydroxyurea","volume":"98","author":"Silver","year":"1983","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.ejon.2006.10.004_bib73","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.20.6.1491","article-title":"Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer","volume":"20","author":"Sloan","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib74","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ejon.2004.06.005","article-title":"Development of and clinical experience with capecitabine (XELODA) in the treatment of solid tumours","volume":"8","author":"Sternberg","year":"2004","journal-title":"European Journal of Oncology Nursing"},{"key":"10.1016\/j.ejon.2006.10.004_bib75","first-page":"670","article-title":"Safety and efficacy of the multidrug resistance inhibitor Incel (Biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel","volume":"8","author":"Toppmeyer","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.ejon.2006.10.004_bib76","first-page":"542","article-title":"Adding Xeloda (capecitabine) to docetaxel significantly improves survival and does not compromise quality of life in patients with metastatic breast cancer","volume":"69","author":"Twelves","year":"2001","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.ejon.2006.10.004_bib77","first-page":"1567","article-title":"Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model","volume":"4","author":"Vail","year":"1998","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.ejon.2006.10.004_bib78","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1046\/j.1365-2133.1998.02487.x","article-title":"Acral erythema induced by chemotherapy with cisplatin","volume":"139","author":"Vakalis","year":"1998","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.ejon.2006.10.004_bib79","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib80","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1365-2230.2001.00782.x","article-title":"Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia","volume":"26","author":"Vassallo","year":"2001","journal-title":"Clinical and Experimental Dermatology"},{"key":"10.1016\/j.ejon.2006.10.004_bib81","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1023\/A:1011181010669","article-title":"A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients","volume":"12","author":"Villalona-Calero","year":"2001","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ejon.2006.10.004_bib82","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-103-2-303_3","article-title":"Cancer-chemotherapy and skin changes","volume":"103","author":"Vogelzang","year":"1985","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.ejon.2006.10.004_bib83","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-111-8-688","article-title":"Pyroxidine for the palmar\u2013plantar erythrodysesthesia syndrome","volume":"111","author":"Vukelja","year":"1989","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.ejon.2006.10.004_bib84","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/85.17.1432","article-title":"Pyridoxine therapy for palmar plantar erythrodysesthesia associated with taxotere","volume":"85","author":"Vukelja","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.ejon.2006.10.004_bib85","doi-asserted-by":"crossref","unstructured":"Ward, S., Kaltenthaler, E., Cowan, J., Brewer, N., 2002. A review of the evidence for the clinical and cost effectiveness of Capecitabine and Tegafur with Uracil for the treatment of metastatic colorectal cancer, National Institute for Health and Clinical Excellence.","DOI":"10.3310\/hta7320"},{"key":"10.1016\/j.ejon.2006.10.004_bib86","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/jnci\/86.7.557","article-title":"Prevention of docetaxel-induced erythrodysesthesia with local hypothermia","volume":"86","author":"Zimmerman","year":"1994","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.ejon.2006.10.004_bib87","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/archderm.131.2.202","article-title":"Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent","volume":"131","author":"Zimmerman","year":"1995","journal-title":"Archives of Dermatology"}],"container-title":["European Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388906001827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388906001827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T11:00:10Z","timestamp":1707649210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1462388906001827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S1462388906001827"],"URL":"https:\/\/doi.org\/10.1016\/j.ejon.2006.10.004","relation":{},"ISSN":["1462-3889"],"issn-type":[{"value":"1462-3889","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}